Freedom Investment Management Inc. Has $201,000 Stake in Kenvue Inc. $KVUE

Freedom Investment Management Inc. trimmed its holdings in Kenvue Inc. (NYSE:KVUE) by 32.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,595 shares of the company’s stock after selling 4,562 shares during the period. Freedom Investment Management Inc.’s holdings in Kenvue were worth $201,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in KVUE. GAMMA Investing LLC raised its position in shares of Kenvue by 33.2% in the first quarter. GAMMA Investing LLC now owns 24,778 shares of the company’s stock valued at $594,000 after buying an additional 6,169 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its position in shares of Kenvue by 4.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock valued at $2,545,000 after buying an additional 4,034 shares in the last quarter. Golden State Wealth Management LLC raised its position in shares of Kenvue by 292.0% in the first quarter. Golden State Wealth Management LLC now owns 3,081 shares of the company’s stock valued at $74,000 after buying an additional 2,295 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its position in Kenvue by 2.6% during the first quarter. Robeco Institutional Asset Management B.V. now owns 103,091 shares of the company’s stock valued at $2,472,000 after purchasing an additional 2,576 shares in the last quarter. Finally, Creative Financial Designs Inc. ADV raised its position in Kenvue by 218.1% during the first quarter. Creative Financial Designs Inc. ADV now owns 4,523 shares of the company’s stock valued at $108,000 after purchasing an additional 3,101 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of Kenvue stock opened at $15.04 on Tuesday. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a twelve month low of $14.05 and a twelve month high of $25.17. The stock has a market cap of $28.87 billion, a price-to-earnings ratio of 20.33, a P/E/G ratio of 2.16 and a beta of 0.72. The company’s fifty day moving average is $17.78 and its 200 day moving average is $20.74.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company had revenue of $3.84 billion for the quarter, compared to analysts’ expectations of $3.94 billion. During the same quarter in the previous year, the firm posted $0.32 earnings per share. Kenvue’s revenue for the quarter was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a yield of 5.5%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. Kenvue’s payout ratio is currently 112.16%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Rothschild & Co Redburn upgraded shares of Kenvue from a “neutral” rating to a “buy” rating and lowered their price objective for the company from $22.50 to $22.00 in a research report on Friday, September 26th. Citigroup lowered their price objective on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, October 9th. Barclays lowered their price objective on shares of Kenvue from $20.00 to $17.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 1st. Redburn Partners set a $22.00 price objective on shares of Kenvue in a research report on Friday, September 26th. Finally, Bank of America lowered their price objective on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average price target of $20.90.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.